胶质母细胞瘤的精准医学进展:系统综述

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL
BioMedicine-Taiwan Pub Date : 2023-06-01 eCollection Date: 2023-01-01 DOI:10.37796/2211-8039.1403
Karan Iyer, Shubham Saini, Suman Bhadra, Sohini Kulavi, Jaya Bandyopadhyay
{"title":"胶质母细胞瘤的精准医学进展:系统综述","authors":"Karan Iyer, Shubham Saini, Suman Bhadra, Sohini Kulavi, Jaya Bandyopadhyay","doi":"10.37796/2211-8039.1403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS).</p><p><strong>Purpose: </strong>With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma.</p><p><strong>Methods: </strong>This review has exhaustively surveyed several pieces of works from various literature databases.</p><p><strong>Conclusion: </strong>It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.</p>","PeriodicalId":51650,"journal":{"name":"BioMedicine-Taiwan","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627207/pdf/","citationCount":"0","resultStr":"{\"title\":\"Precision medicine advancements in glioblastoma: A systematic review.\",\"authors\":\"Karan Iyer, Shubham Saini, Suman Bhadra, Sohini Kulavi, Jaya Bandyopadhyay\",\"doi\":\"10.37796/2211-8039.1403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS).</p><p><strong>Purpose: </strong>With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma.</p><p><strong>Methods: </strong>This review has exhaustively surveyed several pieces of works from various literature databases.</p><p><strong>Conclusion: </strong>It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.</p>\",\"PeriodicalId\":51650,\"journal\":{\"name\":\"BioMedicine-Taiwan\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627207/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BioMedicine-Taiwan\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37796/2211-8039.1403\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioMedicine-Taiwan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37796/2211-8039.1403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:多形性胶质母细胞瘤,通常称为GBM或胶质母细胞细胞瘤,是一种IV级星形细胞瘤。脑肿瘤治疗困难,导致患者预后和生存率差。胶质瘤分为四个不同级别,其中GBM是最差级别的原发性脑肿瘤,生存期不到一年。脑肿瘤的基因组异质性导致被诊断为胶质母细胞瘤的患者出现不同的结果。精准医学专注于这种特定的肿瘤类型,并建议进行专门治疗以获得更好的预后和总体生存率(OS)目的:随着全基因组研究(GWS)的最新进展以及基于遗传、转录组学、蛋白质组学、表观遗传学和代谢组学的脑肿瘤的各种特征,这篇综述讨论了基于胶质母细胞瘤不同类型的精准医学治疗、药物和诊断方法的进展和机遇。方法:本综述对不同文献数据库中的几篇作品进行了详尽的调查。结论:很明显,包括胶质母细胞瘤在内的大多数原发性脑肿瘤都需要特殊而精确的治疗方法来改善预后和OS。在现在和未来,分子理解和发现特定疗法对于神经肿瘤学领域的治疗至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Precision medicine advancements in glioblastoma: A systematic review.

Precision medicine advancements in glioblastoma: A systematic review.

Precision medicine advancements in glioblastoma: A systematic review.

Precision medicine advancements in glioblastoma: A systematic review.

Background: Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS).

Purpose: With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma.

Methods: This review has exhaustively surveyed several pieces of works from various literature databases.

Conclusion: It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BioMedicine-Taiwan
BioMedicine-Taiwan MEDICINE, GENERAL & INTERNAL-
CiteScore
2.80
自引率
5.90%
发文量
21
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信